Skip to main content

Table 1 Estimated incidence and prevalence data for HCC in Germany in 2013

From: Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data

Population/parameter

Total

Study sample population (insured for ≥1 day in 2013)

3,344,257

 New HCC diagnoses

407

 Crude HCC incidence (per 100,000)

12.17

 HCC diagnoses (throughout 2013)

769

 Crude HCC prevalence (per 100,000)

22.99

 Proportion of population with HCC eligible for second-line therapy, mean % (95% CI)a

7.68% (7.02–8.33)

German statutory health system population (at 1 July 2013)

69,854,922

 New HCC diagnoses (extrapolated incidence)b

8841

 Crude HCC incidence (extrapolated) (per 100,000)b

12.66

 HCC diagnoses (extrapolated throughout 2013)

16,685

 Crude HCC prevalence (extrapolated) (per 100,000)b

23.89

 Number eligible for second-line therapy, low–high limitc

1171–1390

Germany – RKI (2013)

 New HCC diagnosesd

5801–7032

 Crude HCC incidence (per 100,000)e

7.18–8.71

 HCC diagnoses (estimated throughout 2013)f

14,697–17,814

 Crude HCC prevalence (estimated throughout 2013) (per 100,000)f

18.20–22.06

 Number eligible for second-line therapy, low–high limitg

1032–1484

  1. C22 International Classification of Diseases, tenth revision code for liver cancer, CI confidence interval, HCC hepatocellular carcinoma, RKI Robert Koch Institute
  2. aMean of estimates for 2012 (7.89% [58/735]), 2013 (7.02% [54/769]) and 2014 (8.12% [66/813])
  3. bPatients with a diagnosis of HCC in 2013, extrapolated from the German Betriebskrankenkasse (BKK) health insurance scheme data (present study sample), age- and gender-adjusted to the entire German statutory health insurance system
  4. cBased on 95% CI for study sample estimate (i.e. 7.02–8.33)
  5. dAssumes that HCC accounts for 66–80% of total liver cancer burden (RKI estimate [15] – reported value in literature [18]) and based on total number of new liver cancer cases reported in 2013 by the RKI (male: 6160; female: 2630)
  6. eCalculated using number of new HCC cases estimated to be reported in 2013 by the RKI [9] as a proportion of the German population reported by the German Federal statistical office/eurostat [19, 20] in 2013 (N = 80,767,463)
  7. fPrevalence of insured patients with C22 diagnosis was the sum of 5-year prevalence in 2012 (n = 10,800) and incidence in 2013 (n = 8790) = 19,590. Since the 10-year prevalence of C22 reported in 2013 (n = 14,990) exceeded the 5-year prevalence for the same year (n = 12,010) by 1.248 times, this factor (1.248) was used to estimate 10-year prevalence in 2012 and correct calculations as follows: NC22 in Germany = (10,800 × 1.248 = 13,478) + 8790 = 22,268 individuals with C22 diagnosis in the course of 2013. Corrections to estimate HCC prevalence were based on the assumption that HCC accounts for 66–80% of total liver cancer burden (RKI estimate – reported value in literature [18])
  8. gAssumes that HCC accounts for 66–80% of the total liver cancer burden (RKI estimate – reported value in literature [18]) and 95% CI for study sample estimates (i.e., 7.02–8.33)
Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us